This section of the web-site contains information on medicines, advertising of which is not foreseen by the legislation. Information in this section is intended for reference only, has exclusively scientific and informative character and should not be treated as advertising information for a wide range of people. According to the current legislation, access to this information is granted to medical and pharmaceutical employees. Please confirm that you are a medical or pharmaceutical employee.
Products
Salofalk®
Salofalk® contains mesalazine as the active substance which is accepted as the gold standard for the treatment of mild to moderate ulcerative colitis. Its action is i.a. anti-inflammatory via factors such as TNF-α and interleukin-1., and is well tolerated, without the side effects of sulfasalazine. The first preparation of mesalazine in the world (1984) was Salofal®, which is actively used today in more than 60 countries1.
All forms of Salofalk® act topically, providing a high concentration of mesalazine directly to the inflamed mucosa with minimal losses of the active substance in the unaffected parts of the gastrointestinal tract. A good correlation between high therapeutically effective local concentration of mesalazine in the lesion and low level of mesalazine in the blood plasma guarantees low level of systemic effects and makes Salofalk® one of the most well tolerated drugs for the treatment of inflammatory bowel diseases. Thanks to this, Salofalk® was approved for use in the pediatric practice1.
According to the recommendations of ECCO, mesalazine in the form of suppositories 1g is the preferred therapy for active proctitis of mild and moderate severity 2. Salofalk® suppositories allows to achieve remission in 91% of patients with active ulcerative proctitis3.
In the treatment of ulcerative colitis, Salofalk® allows to achieve clinical remission in 79% of patients, and the achieved remission persists for 1 year in 75% of patients4,5.
Salofalk® is represented by various forms and dosages, which allows to use a individually approach for each clinical situation.
Salofalk® – mesalazine for effective treatment of ulcerative colitis, prevention of its recurrence and the possibility of choosing a form and dose for each clinical situation.
1. Salofalk® in clinical practice – Freiburg: Dr. Falk Pharma GmbH, 2009.
2. Harbord М. et al. Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. Journal of Crohn’s and Colitis, 2017, 769–784.
3. Аndus T. et al. Clinical trial: a novel high-dose 1g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010 Nov;16(11):1947-56.
4. Lichtenstein G.R. et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010; 32: 990–999.
5. Kruis W. et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313–322.